Published in RMD Open on April 02, 2015
Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis. | NCT03667131
Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Res Ther (2016) 0.78
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis (2016) 0.77
Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. RMD Open (2017) 0.75
Improvements in Fatigue in 1536 Patients with Rheumatoid Arthritis and Correlation with Other Treatment Outcomes: A Post Hoc Analysis of Three Randomized Controlled Trials of Abatacept. Rheumatol Ther (2017) 0.75
The Use of patient Reported Outcome Measures for Rheumatoid Arthritis in Japan: A Systematic Literature Review. Open Rheumatol J (2017) 0.75
Patient-reported outcomes in Asia: evaluation of the properties of the Rheumatoid Arthritis Impact of Disease (RAID) score in multiethnic Asian patients with rheumatoid arthritis. Clin Rheumatol (2016) 0.75
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum (1993) 8.73
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) (2012) 3.47
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol (2014) 2.35
World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl (1994) 2.23
Outcomes from the Patient Perspective Workshop at OMERACT 6. J Rheumatol (2003) 2.20
Incorporating the patient perspective into outcome assessment in rheumatoid arthritis--progress at OMERACT 7. J Rheumatol (2005) 2.18
Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis (2011) 1.97
Rheumatology outcomes: the patient's perspective. J Rheumatol (2003) 1.87
Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol (2007) 1.87
Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford) (2011) 1.82
Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res (2012) 1.62
Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis (2008) 1.57
Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum (2005) 1.57
Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis (2007) 1.55
Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials (2013) 1.47
Rheumatology outcomes: the patient's perspective. A multicentre focus group interview study of Swedish rheumatoid arthritis patients. Rheumatology (Oxford) (2004) 1.46
Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) (2012) 1.37
Patient reported outcomes: looking beyond the label claim. Health Qual Life Outcomes (2010) 1.35
Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis (2008) 1.32
Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes. Arthritis Care Res (Hoboken) (2010) 1.28
Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. OMERACT Committee. J Rheumatol (1993) 1.25
Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) (2013) 1.25
Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. Ann Rheum Dis (2013) 1.10
Updating the OMERACT filter: implications for patient-reported outcomes. J Rheumatol (2014) 0.92
Reliability and sensitivity to change of the Bristol Rheumatoid Arthritis Fatigue scales. Rheumatology (Oxford) (2013) 0.83
Different wording of the Patient Global Visual Analogue Scale (PG-VAS) affects rheumatoid arthritis patients' scoring and the overall Disease Activity Score (DAS28): a cross-sectional study. Musculoskeletal Care (2013) 0.82
Outcomes associated with early rheumatoid arthritis. Expert Rev Pharmacoecon Outcomes Res (2006) 0.80
Quantitative documentation of benefit/risk of new therapies for rheumatoid arthritis: patient questionnaires as an optimal measure in standard care. Clin Exp Rheumatol (2004) 0.79
The EULAR Outcome Measures Library: development and an example from a systematic review for systemic lupus erythematous instruments. Clin Exp Rheumatol (2015) 0.76